Julie O'Neill is VP at ALEXION PHARMACEUTICALS INC (ALXN). They have made 14 open-market trades across 1 company since 2016, most recently 2018-02-28.
CIK 0000899866
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALXN | 42,787 | $7.8M |
Shares reported on the most recent Form 4, priced at the 2018-03-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALXN | SELL | 2018-02-27 | 2018-03-01 | $119.83 | $195K | +5.6% | -5.3% | +1.5% |
| ALXN | SELL | 2018-02-08 | 2018-02-08 | $116.31 | $557K | +7.4% | +16.5% | +7.1% |
| ALXN | SELL | 2018-02-05 | 2018-02-07 | $117.26 | $248K | +2.2% | +8.1% | -1.2% |
| ALXN | SELL | 2017-08-31 | 2017-09-05 | $145.44 | $636K | +1.1% | -0.9% | -23.0% |
| ALXN | SELL | 2017-08-28 | 2017-08-30 | $140.00 | $1.6M | +3.8% | +1.1% | -22.1% |
| ALXN | SELL | 2017-03-02 | 2017-03-06 | $133.80 | $87K | -7.5% | -12.2% | -23.2% |
| ALXN | SELL | 2017-02-27 | 2017-03-01 | $131.41 | $207K | -6.7% | -9.4% | -26.9% |
| ALXN | SELL | 2017-02-06 | 2017-02-08 | $125.69 | $351K | +2.4% | +0.4% | -1.7% |
| ALXN | SELL | 2016-09-02 | 2016-09-02 | $126.29 | $82K | +4.8% | -1.3% | -1.4% |
| ALXN | SELL | 2016-03-02 | 2016-03-04 | $149.55 | $97K | -8.6% | +2.8% | +9.5% |
| ALXN | SELL | 2016-02-29 | 2016-03-01 | $138.91 | $92K | -6.9% | -6.9% | +0.9% |
| ALXN | SELL | 2016-02-08 | 2016-02-08 | $138.02 | $104K | +6.5% | +2.6% | +4.8% |
| ALXN | SELL | 2016-02-05 | 2016-02-08 | $143.23 | $298K | +6.5% | +2.6% | +4.8% |
| ALXN | SELL | 2016-02-05 | 2016-02-08 | $141.83 | $405K | +6.5% | +2.6% | +4.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.